{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:39:06Z","timestamp":1789763946319,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06386-0","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T04:26:29Z","timestamp":1756441589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combination therapies in spinal muscular atrophy: a systematic review"],"prefix":"10.1007","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-8917","authenticated-orcid":false,"given":"Maryam","family":"Bemanalizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leida","family":"Heidary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Sedigh","family":"Dakkali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Hadizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser","family":"Ahmadbeigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoudreza","family":"Ashrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3726-1496","authenticated-orcid":false,"given":"Vahid","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"2","key":"6386_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3233\/JND-221614","volume":"10","author":"V Mansouri","year":"2023","unstructured":"Mansouri V, Heidari M, Bemanalizadeh M, Azizimalamiri R, Nafissi S, Akbari MG et al (2023) The first report of Iranian registry of patients with spinal muscular atrophy. J Neuromuscul Dis 10(2):211\u2013225","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"6386_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT (2015) Spinal muscular atrophy. Neurol Clin 33(4):831\u2013846. https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004","journal-title":"Neurol Clin"},{"key":"6386_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.pediatrneurol.2024.09.024","volume":"161","author":"M Bemanalizadeh","year":"2024","unstructured":"Bemanalizadeh M, Mansouri V (2024) Beyond numbers: a call to action for accurate estimation of spinal muscular atrophy in the Middle East and North Africa region. Pediatr Neurol 161:182\u2013184. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.09.024","journal-title":"Pediatr Neurol"},{"issue":"1","key":"6386_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E (2011) Spinal muscular atrophy. Orphanet J Rare Dis 6(1):71. https:\/\/doi.org\/10.1186\/1750-1172-6-71","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"6386_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M et al (2018) Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28(2):103\u2013115. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005","journal-title":"Neuromuscul Disord"},{"key":"6386_CR6","unstructured":"U.S. Food and Drug Administration (2016) SPINRAZA (nusinersen) package insert. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf . Accessed May 2025"},{"key":"6386_CR7","unstructured":"U.S. Food and Drug Administration (2019) ZOLGENSMA (onasemnogene abeparvovec-xioi) package insert. Available from: https:\/\/www.fda.gov\/media\/126109\/download . Accessed May 2025"},{"key":"6386_CR8","unstructured":"U.S. Food and Drug Administration (2020). EVRYSDI (risdiplam). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213535s000lbl.pdf . Accessed May 2025"},{"issue":"7","key":"6386_CR9","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1007\/s00431-023-04883-8","volume":"182","author":"L Antonaci","year":"2023","unstructured":"Antonaci L, Pera MC, Mercuri E (2023) New therapies for spinal muscular atrophy: where we stand and what is next. Eur J Pediatr 182(7):2935\u20132942. https:\/\/doi.org\/10.1007\/s00431-023-04883-8","journal-title":"Eur J Pediatr"},{"issue":"1","key":"6386_CR10","doi-asserted-by":"publisher","first-page":"e70064","DOI":"10.1111\/bcpt.70064","volume":"137","author":"V Mansouri","year":"2025","unstructured":"Mansouri V, Bemanalizadeh M, Ahmadbeigi N, Shakeri R, Saffar H (2025) Long-term safety and efficacy of AAV9 vectors expressing human SMN1 gene: a preclinical study. Basic Clin Pharmacol Toxicol 137(1):e70064","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"6386_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/s12887-022-03671-x","volume":"22","author":"JW Day","year":"2022","unstructured":"Day JW, Howell K, Place A, Long K, Rossello J, Kertesz N et al (2022) Advances and limitations for the treatment of spinal muscular atrophy. BMC Pediatr 22(1):632","journal-title":"BMC Pediatr"},{"key":"6386_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","volume":"51","author":"D Giess","year":"2024","unstructured":"Giess D, Erdos J, Wild C (2024) An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies. Eur J Paediatr Neurol 51:84\u201392. https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.004","journal-title":"Eur J Paediatr Neurol"},{"key":"6386_CR13","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj 29: 372","DOI":"10.1136\/bmj.n71"},{"key":"6386_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202549","author":"J Mendell","year":"2023","unstructured":"Mendell J, Wigderson M, Alecu I, Yang L, Mehl L, Connolly A (2023) Long-term follow-up of onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1 (P7\u20139.006). Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000202549","journal-title":"Neurology"},{"issue":"3","key":"6386_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/JBIES-22-00430","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J et al (2023) The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth 21(3):494\u2013506. https:\/\/doi.org\/10.11124\/JBIES-22-00430","journal-title":"JBI Evid Synth"},{"issue":"10","key":"6386_CR16","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127\u20132133. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","journal-title":"JBI Evid Synth"},{"issue":"4","key":"6386_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mus.27375","volume":"64","author":"KF Oechsel","year":"2021","unstructured":"Oechsel KF, Cartwright MS (2021) Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1. Muscle Nerve 64(4):487\u2013490. https:\/\/doi.org\/10.1002\/mus.27375","journal-title":"Muscle Nerve"},{"issue":"3.4","key":"6386_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2739\/kurumemedj.MS6934008","volume":"69","author":"D Nanri","year":"2024","unstructured":"Nanri D, Yuge K, Goto K, Kimura T, Yae Y, Mizuochi T et al (2024) Onasemnogene abeparvovec treatment after nusinersen in an infant with spinal muscular atrophy type 1. Kurume Med J 69(3.4):255\u2013259. https:\/\/doi.org\/10.2739\/kurumemedj.MS6934008","journal-title":"Kurume Med J"},{"issue":"23","key":"6386_CR19","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.3390\/jcm10235540","volume":"10","author":"A Mirea","year":"2021","unstructured":"Mirea A, Shelby ES, Axente M, Badina M, Padure L, Leanca M et al (2021) Combination therapy with nusinersen and onasemnogene abeparvovec-xioi in spinal muscular atrophy type I. J Clin Med 10(23):5540. https:\/\/doi.org\/10.3390\/jcm10235540","journal-title":"J Clin Med"},{"issue":"3","key":"6386_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/jpm14030244","volume":"14","author":"A Belancic","year":"2024","unstructured":"Belancic A, Strbad T, Kucan Stiglic M, Vitezic D (2024) Switching from nusinersen to risdiplam: a Croatian real-world experience on effectiveness and safety. J Personalized Med 14(3):244. https:\/\/doi.org\/10.3390\/jpm14030244","journal-title":"J Personalized Med"},{"issue":"2\u20133","key":"6386_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36185\/2532-1900-356","volume":"42","author":"I Bitetti","year":"2023","unstructured":"Bitetti I, Manna MR, Stella R, Varone A (2023) Sequential treatment with nusinersen, Zolgensma((R)) and risdiplam in a paediatric patient with spinal muscular atrophy type 1: a case report. Acta Myol 42(2\u20133):82\u201385. https:\/\/doi.org\/10.36185\/2532-1900-356","journal-title":"Acta Myol"},{"issue":"3","key":"6386_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/CND.0000000000000521","volume":"26","author":"S Chelladurai","year":"2025","unstructured":"Chelladurai S, D\u2019Urso S, Atherton M, Ong MT (2025) Safety of onasemnogene abeparvovec administration to type 1 SMA patients who have received risdiplam. J Clin Neuromuscul Dis 26(3):140\u2013147","journal-title":"J Clin Neuromuscul Dis"},{"issue":"2","key":"6386_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","volume":"12","author":"CA Chiriboga","year":"2023","unstructured":"Chiriboga CA, Bruno C, Duong T, Fischer D, Mercuri E, Kirschner J et al (2023) Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study. Neurol Ther 12(2):543\u2013557","journal-title":"Neurol Ther"},{"issue":"2","key":"6386_CR24","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1002\/mus.27648","volume":"66","author":"L Ferrante","year":"2022","unstructured":"Ferrante L, Melendez\u2010Zaidi A, Lindsey W, Lotze T (2022) Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec\u2010xioi in a premature neonate with type 1 spinal muscular atrophy. Muscle Nerve 66(2):E8\u2013E10","journal-title":"Muscle Nerve"},{"issue":"4","key":"6386_CR25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/mus.27034","volume":"62","author":"Y Harada","year":"2020","unstructured":"Harada Y, Rao VK, Arya K, Kuntz NL, DiDonato CJ, Napchan-Pomerantz G et al (2020) Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve 62(4):550\u2013554. https:\/\/doi.org\/10.1002\/mus.27034","journal-title":"Muscle Nerve"},{"issue":"6","key":"6386_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/acn3.51560","volume":"9","author":"JM Kwon","year":"2022","unstructured":"Kwon JM, Arya K, Kuntz N, Phan HC, Sieburg C, Swoboda KJ et al (2022) An expanded access program of risdiplam for patients with type 1 or 2 spinal muscular atrophy. Ann Clin Transl Neurol 9(6):810\u2013818. https:\/\/doi.org\/10.1002\/acn3.51560","journal-title":"Ann Clin Transl Neurol"},{"issue":"14","key":"6386_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1212\/WNL.0000000000008207","volume":"93","author":"BH Lee","year":"2019","unstructured":"Lee BH, Collins E, Lewis L, Guntrum D, Eichinger K, Voter K et al (2019) Combination therapy with nusinersen and AVXS-101 in SMA type 1. Neurology 93(14):640\u2013641. https:\/\/doi.org\/10.1212\/WNL.0000000000008207","journal-title":"Neurology"},{"issue":"11","key":"6386_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0883073820928784","volume":"35","author":"SE Matesanz","year":"2020","unstructured":"Matesanz SE, Curry C, Gross B, Rubin AI, Linn R, Yum SW et al (2020) Clinical course in a patient with spinal muscular atrophy type 0 treated with nusinersen and onasemnogene abeparvovec. J Child Neurol 35(11):717\u2013723. https:\/\/doi.org\/10.1177\/0883073820928784","journal-title":"J Child Neurol"},{"issue":"7","key":"6386_CR29","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN et al (2021) Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol 78(7):834\u2013841. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1272","journal-title":"JAMA Neurol"},{"key":"6386_CR30","doi-asserted-by":"publisher","first-page":"101997","DOI":"10.1016\/j.eclinm.2023.101997","volume":"59","author":"M Pane","year":"2023","unstructured":"Pane M, Berti B, Capasso A, Coratti G, Varone A, D\u2019Amico A et al (2023) Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na\u00efve patients with spinal muscular atrophy and following switch from other therapies. EClinicalMedicine 59:101997. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101997","journal-title":"EClinicalMedicine"},{"issue":"3","key":"6386_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.36185\/2532-1900-077","volume":"41","author":"M Tosi","year":"2022","unstructured":"Tosi M, Catteruccia M, Cherchi C, Mizzoni I, D\u2019Amico A (2022) Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with risdiplam. Acta Myol 41(3):117\u2013120. https:\/\/doi.org\/10.36185\/2532-1900-077","journal-title":"Acta Myol"},{"issue":"3","key":"6386_CR32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/mus.28329","volume":"71","author":"CE Bekircan-Kurt","year":"2025","unstructured":"Bekircan-Kurt CE, Subramanian S, Chagat S, Mackenzie SJ, Iammarino M, Reash N et al (2025) Transitioning from nusinersen to risdiplam for spinal muscular atrophy in clinical practice: a single-center experience. Muscle Nerve 71(3):414\u2013421. https:\/\/doi.org\/10.1002\/mus.28329","journal-title":"Muscle Nerve"},{"issue":"6","key":"6386_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/mus.28383","volume":"71","author":"E O\u2019Reilly","year":"2025","unstructured":"O\u2019Reilly E, Stimpson G, Rohwer A, Milev E, Wolfe A, Baranello G et al (2025) Characteristics of patients with spinal muscular atrophy who have switched treatments: a multi-center experience in the United Kingdom. Muscle Nerve 71(6):995\u20131005","journal-title":"Muscle Nerve"},{"issue":"2","key":"6386_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mus.28015","volume":"69","author":"JC Powell","year":"2024","unstructured":"Powell JC, Meiling JB, Cartwright MS (2024) A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy. Muscle Nerve 69(2):179\u2013184. https:\/\/doi.org\/10.1002\/mus.28015","journal-title":"Muscle Nerve"},{"issue":"5","key":"6386_CR35","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/mus.28228","volume":"70","author":"Y Yan","year":"2024","unstructured":"Yan Y, Feng Y, Jiang L, Jin J, Mao S (2024) Safety of risdiplam in spinal muscular atrophy patients after short-term treatment with nusinersen. Muscle Nerve 70(5):1095\u20131098. https:\/\/doi.org\/10.1002\/mus.28228","journal-title":"Muscle Nerve"},{"key":"6386_CR36","unstructured":"NCT04488133 (2020) A study of nusinersen among participants with spinal muscular atrophy who received onasemnogene abeparvovec (RESPOND). Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04488133 . Accessed May 2025"},{"key":"6386_CR37","unstructured":"NCT05067790 (2021) A study to evaluate higher dose (HD) nusinersen (BIIB058) in participants with spinal muscular atrophy previously treated with risdiplam (ASCEND). Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05067790. Accessed May 2025"},{"key":"6386_CR38","unstructured":"NCT05522361 (2022) Risdiplam in patients with spinal muscular atrophy previously treated with nusinersen (RISE). Available from:https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05522361. Accessed May 2025"},{"key":"6386_CR39","unstructured":"NCT05386680 (2023) Phase IIIb, open-label, multi-center study to evaluate safety, tolerability and efficacy of OAV101 administered intrathecally to participants with SMA who discontinued treatment with nusinersen or risdiplam (STRENGTH). Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05386680 . Accessed May 2025"},{"key":"6386_CR40","unstructured":"NCT05861986 (2024) A study evaluating\u00a0the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy after gene therapy 2023. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05861986 .\u00a0Accessed May 2025"},{"key":"6386_CR41","unstructured":"NCT05861999 (2023) A study evaluating the effectiveness and safety of risdiplam administered in pediatric patients with spinal muscular atrophy who experienced a plateau or decline in function after gene therapy HINALEA 2). Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05861999. Accessed May 2025"},{"issue":"13","key":"6386_CR42","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJMoa032089","volume":"350","author":"TF Yeh","year":"2004","unstructured":"Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH et al (2004) Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 350(13):1304\u20131313","journal-title":"N Engl J Med"},{"issue":"18","key":"6386_CR43","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1093\/hmg\/ddr288","volume":"20","author":"DY Kwon","year":"2011","unstructured":"Kwon DY, Motley WW, Fischbeck KH, Burnett BG (2011) Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Hum Mol Genet 20(18):3667\u20133677. https:\/\/doi.org\/10.1093\/hmg\/ddr288","journal-title":"Hum Mol Genet"},{"issue":"15_supplement","key":"6386_CR44","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1212\/WNL.94.15_supplement.1828","volume":"94","author":"JW Day","year":"2020","unstructured":"Day JW, Chiriboga CA, Crawford TO, Darras BT, Finkel RS, Connolly AM, AAN Enterprises et al (2020) Onasemnogene abeparvovec-xioi gene-replacement therapy for spinal muscular atrophy type 1 (SMA1): phase 3 US study (STR1VE) update (1828). Neurology 1828. https:\/\/doi.org\/10.1212\/WNL.94.15_supplement.1828","journal-title":"Neurology"},{"key":"6386_CR45","doi-asserted-by":"publisher","first-page":"e14\u2013e5","DOI":"10.1016\/j.ejpn.2017.04.1219","volume":"21","author":"R Finkel","year":"2017","unstructured":"Finkel R, Kuntz N, Mercuri E, Chiriboga C, Darras B, Topaloglu H et al (2017) Efficacy and safety of nusinersen in infants with spinal muscular atrophy (SMA): final results from the phase 3 ENDEAR study. Eur J Paediatr Neurol 21:e14\u2013e5","journal-title":"Eur J Paediatr Neurol"},{"key":"6386_CR46","doi-asserted-by":"publisher","unstructured":"Oskoui M, Day JW, Deconinck N, Mazzone ES, Nascimento A, Saito K et al (2023) Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol 270(5):2547\u20132549. https:\/\/doi.org\/10.1007\/s00415-023-11658-6","DOI":"10.1007\/s00415-023-11658-6"},{"issue":"1","key":"6386_CR47","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K et al (2022) Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 21(1):42\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7","journal-title":"Lancet Neurol"},{"issue":"11","key":"6386_CR48","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/acn3.51889","volume":"10","author":"CM Proud","year":"2023","unstructured":"Proud CM, Mercuri E, Finkel RS, Kirschner J, De Vivo DC, Muntoni F et al (2023) Combination disease\u2010modifying treatment in spinal muscular atrophy: a proposed classification. Ann Clin Transl Neurol 10(11):2155\u20132160. https:\/\/doi.org\/10.1002\/acn3.51889","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"6386_CR49","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1515\/cclm-2023-1311","volume":"62","author":"S Bayoumy","year":"2024","unstructured":"Bayoumy S, Verberk IMW, Vermunt L, Willemse E, den Dulk B, van der Ploeg AT et al (2024) Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges. Clinical Chemistry and Laboratory Medicine (CCLM) 62(7):1252\u20131265. https:\/\/doi.org\/10.1515\/cclm-2023-1311","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM)"},{"key":"6386_CR50","doi-asserted-by":"publisher","unstructured":"Chen Y, Liu R, Cai W, Jiang L, Chen K, Shi J et al (2025) Davunetide promotes structural and functional recovery of the injured spinal cord by promoting autophagy. Neural Regen Res. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-00154","DOI":"10.4103\/NRR.NRR-D-24-00154"},{"issue":"Suppl 1","key":"6386_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40273-021-01105-7","volume":"40","author":"N Paracha","year":"2022","unstructured":"Paracha N, Hudson P, Mitchell S, Sutherland CS (2022) Systematic literature review to assess the cost and resource use associated with spinal muscular atrophy management. Pharmacoeconomics 40(Suppl 1):11\u201338. https:\/\/doi.org\/10.1007\/s40273-021-01105-7","journal-title":"Pharmacoeconomics"},{"key":"6386_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/nu13072400","author":"A Corsello","year":"2021","unstructured":"Corsello A, Scatigno L, Pascuzzi MC, Calcaterra V, Dilillo D, Vizzuso S et al (2021) Nutritional, gastrointestinal and endo-metabolic challenges in the management of children with spinal muscular atrophy type 1. Nutrients. https:\/\/doi.org\/10.3390\/nu13072400","journal-title":"Nutrients"},{"issue":"Suppl 1","key":"6386_CR53","first-page":"P261","volume":"17","author":"S Rudnicki","year":"2016","unstructured":"Rudnicki S, Andrews J, Malik F, Wolff A, Day J (2016) CK-2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy. Amyotroph Lateral Sclerosis Frontotemporal Degeneration 17(Suppl 1):P261","journal-title":"Amyotroph Lateral Sclerosis Frontotemporal Degeneration"},{"issue":"3","key":"6386_CR54","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","volume":"1860","author":"RN Singh","year":"2017","unstructured":"Singh RN, Howell MD, Ottesen EW, Singh NN (2017) Diverse role of survival motor neuron protein. Biochimica et Biophysica Acta (BBA) 1860(3):299\u2013315. https:\/\/doi.org\/10.1016\/j.bbagrm.2016.12.008","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"1","key":"6386_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00431-024-05886-9","volume":"184","author":"M Lavie","year":"2024","unstructured":"Lavie M, Rochman M, Armoni Domany K, Golan Tripto I, Be\u2019er M, Besor O et al (2024) Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study. Eur J Pediatr 184(1):58. https:\/\/doi.org\/10.1007\/s00431-024-05886-9","journal-title":"Eur J Pediatr"},{"issue":"2","key":"6386_CR56","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/jnc.14935","volume":"153","author":"V Pagliarini","year":"2020","unstructured":"Pagliarini V, Guerra M, Di Rosa V, Compagnucci C, Sette C (2020) Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in spinal muscular atrophy cells. J Neurochem 153(2):264\u2013275. https:\/\/doi.org\/10.1111\/jnc.14935","journal-title":"J Neurochem"},{"issue":"1","key":"6386_CR57","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ajhg.2019.05.008","volume":"105","author":"L Torres-Benito","year":"2019","unstructured":"Torres-Benito L, Schneider S, Rombo R, Ling KK, Grysko V, Upadhyay A et al (2019) Ncald antisense oligonucleotide therapy in addition to nusinersen further ameliorates spinal muscular atrophy in mice. Am J Hum Genet 105(1):221\u2013230","journal-title":"Am J Hum Genet"},{"issue":"4","key":"6386_CR58","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.3390\/ijms24044198","volume":"24","author":"A Mui\u00f1os-B\u00fchl","year":"2023","unstructured":"Mui\u00f1os-B\u00fchl A, Rombo R, Ling KK, Zilio E, Rigo F, Bennett CF et al (2023) Long-term SMN-and Ncald-ASO combinatorial therapy in SMA mice and NCALD-ASO treatment in hiPSC-derived motor neurons show protective effects. Int J Mol Sci 24(4):4198","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6386_CR59","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/jcsm.12542","volume":"11","author":"H Zhou","year":"2020","unstructured":"Zhou H, Meng J, Malerba A, Catapano F, Sintusek P, Jarmin S et al (2020) Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. J Cachexia Sarcopenia Muscle 11(3):768\u2013782. https:\/\/doi.org\/10.1002\/jcsm.12542","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"6386_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","volume":"16","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M (2021) Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis 16(1):47. https:\/\/doi.org\/10.1186\/s13023-021-01695-7","journal-title":"Orphanet J Rare Dis"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06386-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:10:33Z","timestamp":1774624233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06386-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["6386"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06386-0","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"583"}}